Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camostat mesilate - Ono Pharmaceutical

Drug Profile

Camostat mesilate - Ono Pharmaceutical

Alternative Names: Foipan; FOY-305; ono 305

Latest Information Update: 21 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ono Pharmaceutical
  • Class Anti-inflammatories; Antineoplastics; Antiulcers; Antivirals; Benzene derivatives; Guanidines; Inorganic sulfur compounds; Small molecules
  • Mechanism of Action Peptide hydrolase inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pancreatitis; Reflux oesophagitis
  • Phase II/III COVID 2019 infections
  • Discontinued Cancer

Most Recent Events

  • 25 Sep 2020 Phase-II/III clinical trials in COVID-2019 infections in United Kingdom (PO) (EudraCT2020-002110-41)
  • 15 Jul 2020 Discontinued - Preclinical for Cancer in Japan (PO)
  • 14 Jul 2020 Academic and Community Cancer Research plans a phase II trial for Severe Acute Respiratory Syndrome associated with COVID-2019 infections in USA in July 2020(NCT04470544)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top